News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
AstraZeneca PLC’s U.S. Sales Tumble As Generics Bite
October 28, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- AstraZeneca Plc, the U.K.’s second- biggest drugmaker, fell the most in almost nine months in London trading after saying fourth-quarter comparisons would be “demanding” as generic competition cuts into profit.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
AstraZeneca
MORE ON THIS TOPIC
Earnings
Sarepta says to ‘exercise prudence’ in setting expectations for Elevidys’ recovery
May 7, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Amgen, Sanofi commit nearly $600M to North American expansions
May 6, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales
May 6, 2026
·
4 min read
·
Annalee Armstrong
Business
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026
May 6, 2026
·
1 min read
·
Gabrielle Masson